- Home
- KALV vs SENEA Comparison
KALV vs SENEA Comparison
Compare KALV & SENEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- SENEA
- Stock Information
- Founded
- KALV N/A
- SENEA 1949
- Country
- KALV United States
- SENEA United States
- Employees
- KALV N/A
- SENEA N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- SENEA Packaged Foods
- Sector
- KALV Health Care
- SENEA Consumer Staples
- Exchange
- KALV Nasdaq
- SENEA Nasdaq
- Market Cap
- KALV 796.4M
- SENEA 710.1M
- IPO Year
- KALV N/A
- SENEA N/A
- Fundamental
- Price
- KALV $11.10
- SENEA $118.47
- Analyst Decision
- KALV Strong Buy
- SENEA
- Analyst Count
- KALV 8
- SENEA 0
- Target Price
- KALV $26.43
- SENEA N/A
- AVG Volume (30 Days)
- KALV 1.5M
- SENEA 46.6K
- Earning Date
- KALV 12-04-2025
- SENEA 11-05-2025
- Dividend Yield
- KALV N/A
- SENEA N/A
- EPS Growth
- KALV N/A
- SENEA N/A
- EPS
- KALV N/A
- SENEA 6.24
- Revenue
- KALV $1,426,000.00
- SENEA $1,571,618,000.00
- Revenue This Year
- KALV N/A
- SENEA N/A
- Revenue Next Year
- KALV $209.38
- SENEA N/A
- P/E Ratio
- KALV N/A
- SENEA $19.57
- Revenue Growth
- KALV N/A
- SENEA 7.30
- 52 Week Low
- KALV $7.30
- SENEA $60.92
- 52 Week High
- KALV $17.28
- SENEA $123.27
- Technical
- Relative Strength Index (RSI)
- KALV 38.98
- SENEA 65.75
- Support Level
- KALV $10.75
- SENEA $112.02
- Resistance Level
- KALV $12.23
- SENEA $123.27
- Average True Range (ATR)
- KALV 0.62
- SENEA 3.18
- MACD
- KALV -0.01
- SENEA 1.00
- Stochastic Oscillator
- KALV 23.41
- SENEA 69.74
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.